Cardurion is a clinical-stage cardiovascular biotechnology company developing new therapeutics for the treatment of heart failure and cardiovascular diseases. Cardurion’s product pipeline includes our lead clinical asset, CRD-733, a PDE-9 inhibitor with the potential to improve cardiac function in heart failure patients. Cardurion has an exclusive licensing agreement with Astellas for the development and commercialization of CRD-733. Additionally, Cardurion has a strong cardiovascular development partnership with Takeda which is fueling drug discovery and preclinical development work being conducted in our internal research laboratories.
Employees: 11-50
Total raised: $260M
Founded date: 2017
Investors 2
| Date | Name | Website |
| 29.10.2021 | Bain Capit... | baincapita... |
| - | Bain Capit... | baincapita... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 16.07.2024 | Series B | $260M | - |
Mentions in press and media 7
| Date | Title | Description |
| 19.07.2024 | The Week’s 10 Biggest Funding Rounds: Cardurion Pharmaceuticals And Human Interest Nab Largest Raises | 5 Shares Email Facebook Twitter LinkedIn Want to keep track of the largest startup funding deals in 2024 with our curated list of $100 million-plus venture deals to U.S.-based companies? Check out The Crunchbase Megadeals Board. This is a w... |
| 16.07.2024 | Cardurion Pharmaceuticals Raises $260M Series B Financing | Cardurion Pharmaceuticals, Inc., a Burlington, MA-based clinical-stage biotechnology company developing next-generation therapeutics for the treatment of cardiovascular diseases, raised $260m in Series B financing. The round was led by Asce... |
| 16.07.2024 | Cardio-focused Cardurion closes hearty $260M series B to challenge statin-dominated status quo | Cardurion Pharmaceuticals was made flush in 2021 thanks to a $300 million investment from Bain Capital. Now, the biotech is looking to challenge the statin-dominated cardiovascular status quo with a $260 million series B fundraising round. ... |
| 28.10.2021 | Robinhood’s new earnings report raises concerns about the company’s reliance on crypto trading | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Si... |
| 28.10.2021 | Robinhood’s new earnings report raises concerns about the company’s reliance on crypto trading | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Morning, folks. This is Fortune reporter Rey Mashayekhi filling in for Lucinda today. Well, Robin... |
| - | Cardurion Pharmaceuticals | “A Boston-based cardiovascular biotechnology company developing next-generation therapeutics for the treatment of heart failure and cardiovascular diseases.” |
| - | Cardurion Pharmaceuticals | “Transforming the treatment of cardiovascular disease and heart failure” |